The Phage Therapy Market is developing across major geographical regions as healthcare systems and biotechnology companies investigate bacteriophage-based approaches for bacterial infections. North America, Europe, Asia-Pacific, South America, and the Middle East & Africa represent important regional markets for research, development, and commercialization.

North America benefits from advanced biotechnology infrastructure, substantial research investment, and a strong ecosystem of pharmaceutical and biotechnology companies. The region has also supported research into alternative approaches for antibiotic-resistant infections. Europe is another important market, supported by academic research institutions, biotechnology companies, and increasing interest in antimicrobial innovation.

Asia-Pacific represents an attractive growth opportunity because of expanding healthcare infrastructure, increasing biotechnology investments, and the rising need for effective infection-management solutions. Research indicates that Asia-Pacific is among the fastest-growing regions in broader phage therapy market forecasts.

South America and the Middle East & Africa are also expected to provide opportunities as healthcare access and research capabilities improve. Veterinary and food-safety applications may contribute additional demand in developing markets.

Future regional expansion will depend on clinical evidence, regulatory frameworks, manufacturing capabilities, investment levels, and awareness of phage-based technologies. Improvements in phage isolation, purification, formulation, storage, and administration could further support commercialization.

Overall, increasing antimicrobial resistance and expanding biotechnology research are expected to remain important factors shaping the global Phage Therapy Market.